Only the osteoanabolic and bone-forming drugs teriparatide (the 1–24 PTH fragment) and romosozumab (an antibody against sclerostin) may accomplish this task, thus they are currently subjected to intense clinical investigation in patients with osteoporosis, especially those with a high risk of fracture. Here, SOST is linked to osteoporosis.